Midatech Pharma (MTPH) Hits New 12-Month Low at $35.38

Midatech Pharma PLC (LON:MTPH) reached a new 52-week low during trading on Monday . The company traded as low as GBX 35.38 ($0.48) and last traded at GBX 40 ($0.54), with a volume of 3000 shares traded. The stock had previously closed at GBX 41 ($0.55).

Separately, N+1 Singer decreased their target price on Midatech Pharma from GBX 140 ($1.88) to GBX 96 ($1.29) and set a “buy” rating on the stock in a research report on Friday, October 13th.

Midatech Pharma (LON:MTPH) last issued its quarterly earnings data on Thursday, September 28th. The company reported GBX (19) (($0.26)) earnings per share for the quarter. Midatech Pharma had a negative return on equity of 43.66% and a negative net margin of 262.24%. The company had revenue of GBX 302 million for the quarter.

WARNING: “Midatech Pharma (MTPH) Hits New 12-Month Low at $35.38” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/20/midatech-pharma-mtph-hits-new-12-month-low-at-35-38.html.

About Midatech Pharma

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply